Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene, Illumina Reach Technology Assessment Deal

NEW YORK (GenomeWeb News) – Trovagene said in a regulatory filing today that it has entered into a deal with Illumina to evaluate the possible integration of Trovagene's transrenal technology with Illumina's sequencing technology.

Specifically, the two firms will assess Trovagene's technology for the isolation, extraction, and genetic analysis of nucleic acids from urine, according to a document filed with the US Securities and Exchange Commission. Trovagene's technology is based on a proprietary method for isolating short, fragmented nucleic acids, it said on its website. The firm has also developed "ultra-short" amplicon assays for detecting transrenal nucleic acids, and developed PCR-based genetic and mutation panels.

All results from its agreement with Illumina will be shared between the parties, and the deal, which was reached on June 20, will terminate either 30 days after the completion of the evaluation of the technologies, or on the one-year anniversary of the agreement, whichever comes first, unless extended by mutual agreement.

Financial and other terms were not disclosed.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.